{
    "nctId": "NCT02053246",
    "officialTitle": "Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure",
    "inclusionCriteria": "* Adults (\u2265 18 years of age) with World Health Organization Group 2 Pulmonary Hypertension (Mean pulmonary artery pressure \u2265 25 mmHg and pulmonary capillary wedge pressure \u2265 15 mmHg)\n* New York Heart Association class II-IV symptoms\n* Left ventricular ejection fraction (LVEF) \u2265 45%\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Other causes of heart failure other than diastolic dysfunction, such as restrictive cardiomyopathy or infiltrative cardiomyopathy\n* Women who are pregnant or nursing\n* Liver cirrhosis,\n* Primary valvular disease\n* Acute coronary syndrome\n* Causes of PH other than that of heart failure, such as: chronic thromboembolic PH, sickle-cell disease, or sarcoidosis\n* Severe bradycardia or greater than 1st degree heart block\n* Decompensated heart failure\n* Current use of a third generation beta-blocker (nebivolol, carvedilol, or labetalol) or high dose of any beta-blockers (greater than 100 mg daily of metoprolol, or equivalent)"
}